OBJECTIVES: To evaluate a novel series of quinoxaline 1,4-di-N-oxides for in vitro activity against Mycobacterium tuberculosis and for efficacy in a mouse model of tuberculosis (TB). METHODS: Ketone and amide derivatives of quinoxaline 1,4-di-N-oxide were evaluated in in vitro and in vivo tests including: (i) activity against M. tuberculosis resistant to currently used antitubercular drugs including multidrug-resistant strains (MDR-TB resistant to isoniazid and rifampicin); (ii) activity against non-replicating persistent (NRP) bacteria; (iii) MBC; (iv) maximum tolerated dose, oral bioavailability and in vivo efficacy in mice; and (v) potential for cross-resistance with another bioreduced drug, PA-824. RESULTS: Ten compounds were tested on single drug-resistant M. tuberculosis. In general, all compounds were active with ratios of MICs against resistant and non-resistant strains of <or=4.00. One compound, 5, was orally active in a murine model of TB, bactericidal, active against NRP bacteria and active on MDR-TB and poly drug-resistant clinical isolates (resistant to 3-5 antitubercular drugs). CONCLUSIONS: Quinoxaline 1,4-di-N-oxides represent a new class of orally active antitubercular drugs. They are likely bioreduced to an active metabolite, but the pathway of bacterial activation was different from PA-824, a bioreducible nitroimidazole in clinical trials. Compound 5 was bactericidal and active on NRP organisms indicating that activation occurred in both growing and non-replicating bacteria leading to cell death. The presence of NRP bacteria is believed to be a major factor responsible for the prolonged nature of antitubercular therapy. If the bactericidal activity and activity on non-replicating bacteria in vitro translate to in vivo conditions, quinoxaline 1,4-di-N-oxides may offer a path to shortened therapy.
OBJECTIVES: To evaluate a novel series of quinoxaline 1,4-di-N-oxides for in vitro activity against Mycobacterium tuberculosis and for efficacy in a mouse model of tuberculosis (TB). METHODS:Ketone and amide derivatives of quinoxaline 1,4-di-N-oxide were evaluated in in vitro and in vivo tests including: (i) activity against M. tuberculosis resistant to currently used antitubercular drugs including multidrug-resistant strains (MDR-TB resistant to isoniazid and rifampicin); (ii) activity against non-replicating persistent (NRP) bacteria; (iii) MBC; (iv) maximum tolerated dose, oral bioavailability and in vivo efficacy in mice; and (v) potential for cross-resistance with another bioreduced drug, PA-824. RESULTS: Ten compounds were tested on single drug-resistant M. tuberculosis. In general, all compounds were active with ratios of MICs against resistant and non-resistant strains of <or=4.00. One compound, 5, was orally active in a murine model of TB, bactericidal, active against NRP bacteria and active on MDR-TB and poly drug-resistant clinical isolates (resistant to 3-5 antitubercular drugs). CONCLUSIONS:Quinoxaline 1,4-di-N-oxides represent a new class of orally active antitubercular drugs. They are likely bioreduced to an active metabolite, but the pathway of bacterial activation was different from PA-824, a bioreducible nitroimidazole in clinical trials. Compound 5 was bactericidal and active on NRP organisms indicating that activation occurred in both growing and non-replicating bacteria leading to cell death. The presence of NRP bacteria is believed to be a major factor responsible for the prolonged nature of antitubercular therapy. If the bactericidal activity and activity on non-replicating bacteria in vitro translate to in vivo conditions, quinoxaline 1,4-di-N-oxides may offer a path to shortened therapy.
Authors: Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: Umashankar Das; Swagatika Das; Brian Bandy; Dennis K J Gorecki; Jonathan R Dimmock Journal: Eur J Med Chem Date: 2010-07-24 Impact factor: 6.514
Authors: Sidharth Chopra; Gary A Koolpe; Arlyn A Tambo-Ong; Karen N Matsuyama; Kenneth J Ryan; Tran B Tran; Rupa S Doppalapudi; Edward S Riccio; Lalitha V Iyer; Carol E Green; Baojie Wan; Scott G Franzblau; Peter B Madrid Journal: J Med Chem Date: 2012-06-25 Impact factor: 7.446
Authors: Ana Carolina Alves de Paula E Silva; Caroline Barcelos Costa-Orlandi; Fernanda Patrícia Gullo; Fernanda Sangalli-Leite; Haroldo Cesar de Oliveira; Julhiany de Fátima da Silva; Liliana Scorzoni; Nayla de Souza Pitangui; Suélen Andrea Rossi; Tatiane Benaducci; Vanessa Gonçalves Wolf; Luis Octávio Regasini; Maicon Segalla Petrônio; Dulce Helena Siqueira Silva; Vanderlan S Bolzani; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini Journal: Evid Based Complement Alternat Med Date: 2014-11-20 Impact factor: 2.629
Authors: Sean Ekins; Peter B Madrid; Malabika Sarker; Shao-Gang Li; Nisha Mittal; Pradeep Kumar; Xin Wang; Thomas P Stratton; Matthew Zimmerman; Carolyn Talcott; Pauline Bourbon; Mike Travers; Maneesh Yadav; Joel S Freundlich Journal: PLoS One Date: 2015-10-30 Impact factor: 3.240
Authors: Isidro Palos; Julieta Luna-Herrera; Edgar E Lara-Ramírez; Alejandra Loera-Piedra; Emanuel Fernández-Ramírez; Ma Guadalupe Aguilera-Arreola; Alma D Paz-González; Antonio Monge; Baojie Wan; Scott Franzblau; Gildardo Rivera Journal: Molecules Date: 2018-06-15 Impact factor: 4.411